Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The limited treatment options for triple-negative breast cancer with brain metastasis (TNBC-BM) have left the door of further drug development for these patients wide open. Although immunotherapy via monoclonal antibodies has shown some promising results in several cancers including TNBC, it cannot be considered the most effective treatment for brain metastasis. This is due to the protective role of the blood-brain barrier (BBB) which limits the entrance of most drugs, especially the bulky ones such as antibodies, to the brain. For a drug to traverse the BBB via passive diffusion, various physicochemical properties should be considered. Since natural medicine has been a key inspiration for the development of the majority of current medicines, in this paper, we review several naturally-derived molecules which have the potential for immunotherapy via blocking the interaction of programmed cell death protein-1 (PD-1) and its ligand, PD-L1. The mechanism of action, physicochemical properties and pharmacokinetics of these molecules and their theoretical potential to be used for the treatment of TNBC-BM are discussed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777321 | PMC |
| http://dx.doi.org/10.3390/cancers14246258 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ASO Visual Abstract: The Metaplastic Conundrum: An NCDB analysis of Metaplastic Versus Triple-Negative Ductal Breast Cancer.
Ann Surg Oncol
September 2025
Cincinnati Research in Outcomes and Safety in Surgery (CROSS) Research Group, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer.
Mol Diagn Ther
September 2025
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.
Background And Objective: Sacituzumab govitecan, an anti-trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate, has been approved by both the US Food and Drug Administration and European Medicines Agency for patients with metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. Although TROP2 evaluation is not required for patient selection, survival data from the ASCENT trial show improved response rates in patients with high TROP2 expression by immunohistochemistry. However, there is no standardized testing assay for these patients.
View Article and Find Full Text PDFClinicopathologic features and contralateral breast cancer risk in BRCA1/2 pathogenic variant carriers: a multicenter registry study of Japanese women.
Breast Cancer Res Treat
September 2025
Departments of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Purpose: This large-scale study presents the clinicopathological characteristics and cumulative incidence of contralateral breast cancer (CBC) in Japanese BRCA1/2 pathogenic variant carriers, including cases diagnosed after the implementation of national insurance coverage.
Methods: We analyzed 2949 breast cancer cases from the registry database of the Japanese Organization of Hereditary Breast and Ovarian Cancer.
Results: BRCA1 carriers predominantly developed triple-negative breast cancer, whereas BRCA2 carriers more frequently developed luminal-type tumors, with a younger age of onset observed in BRCA1 carriers.
Clathrin-Mediated Endocytosis for Enhanced Apoptosis Induction and Cellular Imaging in Triple-Negative Breast Cancer by Casein-Protected Blue-Emissive Carbon Dots.
ACS Appl Bio Mater
September 2025
Chemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
The development of multifunctional nanoplatforms capable of drug delivery and real-time cellular imaging remains a key challenge in cancer theranostics. Herein, we report the development of a casein-protected maleic acid-derived nitrogen-doped carbon dot-based luminescent nanoplatform (MNCD@Cas NPs) for efficient delivery of the anticancer drug doxorubicin hydrochloride (DOX) to triple-negative breast cancer cells. Synthesized via a facile two-step method, the MNCD@Cas NPs exhibit bright blue fluorescence (λ = 390 nm), high water dispersibility, excellent colloidal stability, and substantial DOX loading capacity (∼84%) driven by electrostatic interactions.
View Article and Find Full Text PDFStrategic Timing of Gene Silencing: Cellular Kinetics-Based Administration of siRNA for Optimized Photothermal Cancer Treatment.
Adv Sci (Weinh)
September 2025
Department of Biomedical Engineering, College of Engineering and Applied Sciences, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, 210023, China.
Heat shock protein 70 (HSP70) represents a critical barrier to effective mild-temperature photothermal therapy (MPTT), limiting its clinical utility in aggressive cancers like triple-negative breast cancer (TNBC). While small interfering RNA (siRNA)-mediated HSP70 suppression offers a promising solution, optimal timing for this therapeutic combination remains unexplored. Here, it is demonstrated that precisely timed administration significantly enhances MPTT efficacy through systematic temporal characterization of HSP70 expression dynamics.
View Article and Find Full Text PDF